INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 459m ago
HOUSE PTR59m ago
SEC 13F58m ago
ROBINHOOD CHAIN58m ago
Corporate insider
BS

Bulis Veronica Sanchez

VP, Corporate ControllerCIK 0002095702

EDGAR filingsOpen in network
Disclosed transactions7
Buys / sells0 / 6
Max Insider Score37
Connections1with evidence

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
27
BS
Bulis Veronica SanchezVP, Corporate Controller
LYELLyell Immunopharma, Inc.
Open-market sale
SELL$8,905
621 sh
Aug 10, 2026Aug 11, 2026
traded Aug 10, 2026
+1dSEC FORM 4

Evidence

Verified connections

  • Insider ofevidence
    Lyell Immunopharma, Inc.VP, Corporate Controller · Nov 12, 2025
37
BS
Bulis Veronica SanchezVP, Corporate Controller
LYELLyell Immunopharma, Inc.
Open-market sale
SELL
$4,103
217 sh
May 11, 2026
Jun 15, 2026
traded May 11, 2026
+35d
SEC FORM 4

Evidence

17
BS
Bulis Veronica SanchezVP, Corporate Controller
LYELLyell Immunopharma, Inc.
Grant or award
A—
8,750 sh
Feb 10, 2026Feb 11, 2026
traded Feb 10, 2026
+1dSEC FORM 4

Evidence

27
BS
Bulis Veronica SanchezVP, Corporate Controller
LYELLyell Immunopharma, Inc.
Open-market sale
SELL$5,872
254 sh
Feb 10, 2026Feb 11, 2026
traded Feb 10, 2026
+1dSEC FORM 4

Evidence

27
BS
Bulis Veronica SanchezVP, Corporate Controller
LYELLyell Immunopharma, Inc.
Open-market sale
SELL$30K
936 sh
Dec 30, 2025Jan 6, 2026
traded Dec 30, 2025
+7dSEC FORM 4

Evidence

31
BS
Bulis Veronica SanchezVP, Corporate Controller
LYELLyell Immunopharma, Inc.
Open-market sale
SELL$44K
1,136 sh
Dec 24, 2025Jan 6, 2026
traded Dec 24, 2025
+13dSEC FORM 4

Evidence

31
BS
Bulis Veronica SanchezVP, Corporate Controller
LYELLyell Immunopharma, Inc.
Open-market sale
SELL$3,848
239 sh
Nov 10, 2025Nov 12, 2025
traded Nov 10, 2025
+2dSEC FORM 4

Evidence